Third Arc Bio
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications
$52MSeries A+
Role not disclosedAV
AbbVie Ventures
Activity from announced rounds
Activity in this selectionSeries A
AbbVie Ventures is AbbVie’s corporate venture investment arm. Company and university announcements identify it as an investor in Third Arc Bio and Cloverleaf Bio.
Recorded funding activity
The two companies pursue different therapeutic approaches. Third Arc develops multifunctional antibodies for oncology and immunology; Cloverleaf engineers transfer RNA for cancer treatment. The recorded activity includes Third Arc’s Series A extension and Cloverleaf’s seed financing, linking AbbVie Ventures to both later syndicate support and early company formation.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $52M 1 disclosed · full round size, not this investor’s share